| 英文别名 |
1-Pyrrolidinecarboxamide, N-[3-[2-[[(1R)-2-hydroxy-1-methylethyl]amino]-6-(4-morpholinyl)-4-pyridinyl]-4-methylphenyl]-3-(2,2,2-trifluoroethyl)-, (3S)-;exarafenib;NSC-852991;(S)-N-(3-(2-(((R)-1-hydroxypropan-2- yl)amino)-6-morpholinopyridin-4-yl)-4- methylphenyl)-3-(2,2,2- trifluoroethyl)pyrrolidine-1-carboxamide;EX-A7314;US11098031, Example 14;2VPX8HL8AB;compound 15 [Chen et al., 2024];example 14 (WO2021081375A1);HY-147268;CHEMBL5095099;MS-29671;BDBM514652;2639957-39-2;SCHEMBL23275448;(3S)-N-[3-[2-[[(2R)-1-hydroxypropan-2-yl]amino]-6-morpholin-4-ylpyridin-4-yl]-4-methylphenyl]-3-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide;GTPL12095;DA-53083;CS-0542473;KIN-2787 free base;(3S)-N-(3-(2-(((2R)-1-hydroxypropan-2-yl)amino)-6-morpholin-4-ylpyridin-4-yl)-4-methylphenyl)-3-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide;F84504;Exarafenib [INN];NSC852991;UNII-2VPX8HL8AB;(S)-N-(3-(2-(((R)-1-Hydroxypropan-2-yl)amino)-6-morpholinopyridin-4-yl)-4-methylphenyl)-3-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide;(3~{S})-~{N}-[4-methyl-3-[2-morpholin-4-yl-6-[[(2~{R})-1-oxidanylpropan-2-yl]amino]pyridin-4-yl]phenyl]-3-[2,2,2-tris(fluoranyl)ethyl]pyrrolidine-1-carboxamide;pan-Raf Inhibitor KIN-2787;KIN2787;Exarafenib?;B-Raf Inhibitor KIN-2787;WJ9;KIN 2787;(3S)-N-(3-(2-(((2R)-1-Hydroxypropan-2-yl)amino)-6- (morpholin-4-yl)pyridin-4-yl)-4-methylphenyl)-3-(2,2,2- trifluoroethyl)pyrrolidine-1-carboxamide;Exarafenib [WHO-DD];(3S)-N-{3-[2-{[(2R)-1-hydroxypropan-2-yl]amino}-6- (morpholin-4-yl)pyridin-4-yl]-4-methylphenyl}-3-(2,2,2- trifluoroethyl)pyrrolidine-1-carboxamide;1-Pyrrolidinecarboxamide, N-(3-(2-(((1R)-2-hydroxy-1-methylethyl)amino)-6-(4-morpholinyl)-4-pyridinyl)-4-methylphenyl)-3-(2,2,2-trifluoroethyl)-, (3S)-;N-[3-[2-[[(1R)-2-hydroxy-1-methylethyl]amino]-6-(4-morpholinyl)-4- pyridinyl]-4-methylphenyl]-3-(2,2,2-trifluoroethyl)-, (3S)-1-Pyrrolidinecarboxamide;example 14 [WO2021081375A1];compound 15 (Chen et al., 2024);KIN-2787 |